1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A

2.43
HKD
+0.03
(+1.25%)
8.81BMarket Cap
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A
HKEX:1349
(Hong Kong Exchange)

Recent

price

2.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.04
0.05
0.09
0.14
0.14
0.18
0.19
0.15
0.23
0.31
0.24
0.31
0.28
0.23
0.19
0.19
- -
Revenue per Share
- -
0.01
0.02
0.03
0.04
0.04
0.04
0.02
0.03
0.07
0.05
0.06
0.04
0.03
0.01
-0.04
- -
Basic EPS, GAAP
-0.01
0.01
- -
0.01
0.01
0.02
0.03
-0.01
0.04
0.07
0.02
0.04
0.02
-0.01
-0.02
0.03
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
0.02
0.02
0.01
0.02
0.02
0.03
0.01
- -
Dividend per Share
0.06
0.07
0.18
0.16
0.2
0.22
0.26
0.27
0.29
0.28
0.54
0.59
0.62
0.63
0.62
0.57
0.58
Book Value per Share
0.05
0.07
0.18
0.16
0.2
0.22
0.25
0.26
0.26
0.26
0.52
0.56
0.59
0.61
0.6
0.55
0.56
Tangible Book Value per Share
2,531
2,531
2,531
3,081
3,290
3,290
3,290
3,290
3,290
3,290
3,527
3,710
3,672
3,686
3,695
3,695
1,707
Basic Weighted Avg Shares
92
134
233
416
471
579
622
498
742
1,029
834
1,140
1,031
851
709
686
- -
Sales/Revenue/Turnover
7.5
30.33
26.68
25.04
25.78
23.74
23.07
12.05
12.85
24.42
20.19
16.68
12.06
15.28
0.7
-24.84
- -
Operating Margin (%)
8
5
10
15
24
28
30
43
57
57
22
23
23
20
18
14
- -
Depreciation Expense
4
31
53
87
118
128
139
75
112
227
165
213
138
109
40
-157
- -
Net Income, GAAP
70.27
13.97
9.12
15.57
13.74
12.95
13.81
14.66
3.17
10.42
7.04
1.64
- -
- -
- -
- -
- -
Effective Tax Rate (%)
3.98
23.02
22.86
20.97
25.11
22.04
22.3
15.13
15.11
22.09
19.75
18.71
13.38
12.77
5.6
-22.96
- -
Profit Margin (%)
61
116
42
307
358
394
476
469
571
567
1,599
1,400
1,396
1,364
1,356
1,240
1,304
Working Capital
17
50
40
25
- -
- -
- -
- -
- -
2
14
23
16
11
14
9
7
LT Debt
169
201
260
566
676
766
873
892
954
933
2,008
2,190
2,253
2,359
2,305
2,117
2,153
Total Equity
0.87
13.88
17.16
18.22
16.98
16.56
13.87
6.27
8.24
19.58
10.19
10.01
- -
- -
- -
- -
- -
Return on Invested Capital (%)
0.87
12.84
17.86
19.24
19.53
16.91
16.02
9.44
13.07
21.86
10.93
10.13
- -
- -
- -
- -
- -
Return on Capital (%)
2.68
19.93
27.03
23.08
19.98
18.46
17.6
8.77
12.35
24.25
11.19
10.15
6.2
4.71
1.7
-7.12
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'24
Jun'24
Jun'26
ST Debt
- -
3
5
LT Borrowings
- -
- -
- -
LT Finance Leases
10
9
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,718
3,718
3,718
Market Capitalization
7,380
6,193
7,623

Working Capital

CNY

•

in mil. unless spec.
Mar'24
Jun'24
Jun'26
Total Current Assets
1,833
1,870
1,540
Cash, Cash Equivalents & STI
1,233
1,222
1,223
Accounts Receivable, Net
452
448
189
Inventories
47
53
28
Total Current Liabilities
453
481
236
Payables & Accruals
- -
- -
- -
ST Debt
- -
3
5
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.23%
1.23%
-8.18%
Free Cash Flow
-117.74%
-49.04%
-284.23%
Net Income, GAAP
-49.97%
-117.34%
-496.23%
Sales/Revenue/Turnover
4.59%
-2.05%
-3.33%
Total Cash Common Dividend
7.88%
-5.2%
-66.67%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
148
260
- -
- -
709
2025
- -
- -
- -
- -
686
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.07
- -
- -
0.01
2025
- -
- -
- -
- -
-0.04
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is a Shanghai-based biopharmaceutical company specializing in the research, development, manufacturing, and marketing of innovative drugs and medical devices. Founded in 1996 and headquartered in Shanghai, China, the company operates across multiple R&D platforms, including genetic engineering, photodynamic therapy, nano-technology, and oral solid preparations. Its product portfolio comprises genetic engineering platform drugs such as CD30-DM1 antibody-drug conjugates (ADC) completed Phase I clinical trials for tumors; Trop2-SN38 ADC in Phase III trials for triple-negative breast cancer; Trop2-BB05, DLL3-BB05, and HER2 ADCs in Phase I clinical stages targeting various tumors. It also develops photodynamic technical platform drugs like hemoporfin for port wine stain (completed Phase IV trial) and multiple aminolevulinic acid formulations targeting cervical diseases, actinic keratosis, acne, gliomas, bladder cancer, and surgical visualization applications. Additionally, the company offers osmotic pump technology platform drugs such as controlled-release carbidopa/levodopa tablets (completed Phase II trials for early Parkinson's disease) and obeticholic acid for hepatobiliary and autoimmune diseases. Beyond pharmaceuticals, it provides medical diagnostic products, clinical laboratory analysis instruments and software, daily necessities, technology development, transfer, consulting, and promotion services. Major subsidiaries include Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd., Fernovelty (Hong Kong) Holdings Ltd., and Shanghai Tracing Bio-technology Co., Ltd. Recent significant developments at Shanghai Fudan-Zhangjiang include the dissolution of its Supervisory Committee and appointment of an employee director in late 2025. The company continues to advance its broader strategy in innovative drug commercialization, notably progressing its Trop2-SN38 ADC through Phase III trials and expanding clinical trial work on its BB05 linker-drug platform. The company has invested in scaling antibody-drug conjugate production at its Taizhou facility to support commercial readiness. It is also expanding photodynamic therapy commercialization and has made organizational governance amendments to enhance oversight in 2025. The company remains focused on strengthening industrial capabilities and accelerating innovation-driven growth through collaborations and technological enhancements in biopharmaceutical development and production. Shanghai Fudan-Zhangjiang operates in the innovative drug and medical device segments primarily serving oncology, dermatology, autoimmune, and other specialized therapeutic areas. It markets products domestically in China while actively advancing clinical programs and building production capacity to compete in global biotech markets. The company is publicly listed on the STAR Market of the Shanghai Stock Exchange under ticker 688505.SS and also on the Hong Kong Stock Exchange under 1349.HK, reflecting its A+H share structure. The comprehensive pipeline, platform technologies, recent governance reforms, and strategic investments underscore its commitment to becoming a leading integrated biopharma enterprise in China and beyond.